To date, a number of ER-targeting conjugates have been reported which attempt to exploit the high affinity and receptor selectivity of estrogen receptor ligands to deliver cytotoxic drugs to tumour cells [14,15,16,17,18]. This evidence concerns the gene ESR1 and neoplasm.